ETX — E-Therapeutics Income Statement
0.000.00%
Last trade - 00:00
- £58.58m
- £27.19m
- £0.48m
2019 January 31st | 2020 January 31st | 2021 January 31st | 2022 January 31st | 2023 January 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 0.044 | 0.456 | 0.317 | 0.477 | 0.475 |
Cost of Revenue | |||||
Gross Profit | 0.044 | 0.456 | 0.317 | 0.477 | 0.475 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Depreciation and Amortization | |||||
Total Operating Expenses | 5.16 | 3.34 | 4.8 | 10 | 10.7 |
Operating Profit | -5.11 | -2.89 | -4.49 | -9.57 | -10.2 |
Total Net Non Operating Interest Income / Expense | |||||
Net Income Before Taxes | -5.08 | -2.87 | -4.47 | -9.52 | -9.77 |
Provision for Income Taxes | |||||
Net Income After Taxes | -4 | -2.35 | -3.68 | -8.07 | -8.27 |
Net Income Before Extraordinary Items | |||||
Net Income | -4 | -2.35 | -3.68 | -8.07 | -8.27 |
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -4 | -2.35 | -3.68 | -8.07 | -8.27 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.015 | -0.009 | -0.01 | -0.016 | -0.015 |